Jayanthi Rajendran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jayanthi Rajendran has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Abu Raghavan Srinivasan
Mahatma Gandhi Medical College and Research Institute
1 shared publication - Desai Vidya Sripad
Department of Biochemistry, All India Institute of Medical Sciences, Mangalagiri, Guntur, Andhra Pradesh, India
1 shared publication - Priyanka1 shared publication
- Rajeswari Murugesan
Department of Biostatistics, Jawaharlal Institute of Post Graduate Medical Education & Research (JIPMER), Puducherry, 605006, India
1 shared publication - Saidaiah Ikkurthi
AIIMS, Mangalagiri
1 shared publication - Suresh Vaikkakara
AIIMS, Mangalagiri
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Springer Nature in Research Square
Intelectin-1 (ITLN1) Val109Asp (rs2274907) polymorphism: Association with circulating Omentin-1 Levels and Metaflammation in Men with Type 2 Diabetes
Aim Omentin-1 is an adipokine associated with insulin sensitivity and inflammatory processes, while the ITLN1 Val109Asp (rs2274907) variant has been implicated in metabolic phenotypes. We investigated its association with circulating omentin-1 and a metaflammatory phenotype in men with type 2 diabetes mellitus (T2DM). Methods In this cross-sectional study, 225 men with T2DM were genotyped for ITLN1 Val109Asp (TT, AT, and AA). Anthropometric, glycaemic, insulin-resistance, lipid, inflammatory, and haematological parameters were compared across genotypes. Associations between circulating omentin-1 and metabolic, inflammatory, and haematological parameters were assessed using Spearman correlation. Logistic regression evaluated associations between the variant and obesity under dominant, recessive, and additive models. Receiver operating characteristic analysis assessed discrimination of low circulating omentin-1. Results Omentin-1 concentrations decreased progressively from TT to AT to AA genotypes [749.6, 627.9, and 483.2 ng/L, respectively; P < 0.001], whereas BMI, HOMA-IR, METS-IR, lipid abnormalities, and inflammatory markers showed less favourable profiles in the AA group. Genotype and allele distributions differed across BMI phenotypes (P = 0.027 and P = 0.002, respectively). Omentin-1 was inversely correlated with BMI, WHR, HOMA-IR, and METS-IR and positively correlated with QUICKI across genotype groups. Each additional A allele was associated with higher odds of obesity (age-adjusted OR 1.97, 95% CI 1.27–3.05; P = 0.002). IL-8 showed the highest discrimination for low omentin-1 (AUC 0.976, 95% CI 0.959–0.992). Conclusion ITLN1 Val109Asp was associated with circulating omentin-1 concentrations and a metaflammatory phenotype in men with T2DM, linking genetic variation with a metabolic–inflammatory profile.
- 5 October 2026
- Published by Springer Nature in Research Square
Open AccessIntelectin-1 (ITLN1) Val109Asp (rs2274907) polymorphism: Association with circulating Omentin-1 Levels and Metaflammation in Men with Type 2 Diabetes
Aim Omentin-1 is an adipokine associated with insulin sensitivity and inflammatory processes, while the ITLN1 Val109Asp (rs2274907) variant has been implicated in metabolic phenotypes. We investigated its association with circulating omentin-1 and a metaflammatory phenotype in men with type 2 diabetes mellitus (T2DM). Methods In this cross-sectional study, 225 men with T2DM were genotyped for ITLN1 Val109Asp (TT, AT, and AA). Anthropometric, glycaemic, insulin-resistance, lipid, inflammatory, and haematological parameters were compared across genotypes. Associations between circulating omentin-1 and metabolic, inflammatory, and haematological parameters were assessed using Spearman correlation. Logistic regression evaluated associations between the variant and obesity under dominant, recessive, and additive models. Receiver operating characteristic analysis assessed discrimination of low circulating omentin-1. Results Omentin-1 concentrations decreased progressively from TT to AT to AA genotypes [749.6, 627.9, and 483.2 ng/L, respectively; P < 0.001], whereas BMI, HOMA-IR, METS-IR, lipid abnormalities, and inflammatory markers showed less favourable profiles in the AA group. Genotype and allele distributions differed across BMI phenotypes (P = 0.027 and P = 0.002, respectively). Omentin-1 was inversely correlated with BMI, WHR, HOMA-IR, and METS-IR and positively correlated with QUICKI across genotype groups. Each additional A allele was associated with higher odds of obesity (age-adjusted OR 1.97, 95% CI 1.27–3.05; P = 0.002). IL-8 showed the highest discrimination for low omentin-1 (AUC 0.976, 95% CI 0.959–0.992). Conclusion ITLN1 Val109Asp was associated with circulating omentin-1 concentrations and a metaflammatory phenotype in men with T2DM, linking genetic variation with a metabolic–inflammatory profile.
- Open Access
- 19 May 2026
- Published by Springer Nature in Research Square
The Hemodynamic-Enzymatic Axis: The Interplay of Mean Arterial Pressure and Renalase in Diabetic Kidney Disease and Diabetic Foot Ulcers
Background & Objective: The global burden of Diabetes Mellitus (DM) has transitioned into a systemic crisis characterized by Diabetic Kidney Disease (DKD) and Diabetic Foot Ulcers (DFU). This study investigates the heart-kidney-limb axis, specifically examining the role of Mean Arterial Pressure (MAP) and Serum Renalase as biomarkers for the transition from metabolic dysfunction to irreversible microvascular damage and mechanical barotrauma. Methods: A cross-sectional study was conducted at a tertiary care hospital in South India from January to July 2025. 120 participants were divided into four groups (n=30 each): Control, Type 2 Diabetes (T2DM), DKD, and DFU. Clinical assessments included blood pressure (to calculate MAP), eGFR, HbA1c, HOMA-IR, and Serum Renalase. Statistical analysis utilized Pearson’s correlation and Receiver Operating Characteristic (ROC) curves to determine diagnostic accuracy. Results: A progressive increase in MAP, Serum Renalase, and HOMA-IR was observed across groups (p < 0.01). Serum Renalase showed a strong negative correlation with eGFR (r = -0.76, p < 0.001), supporting an Accumulation Paradox where levels rise as renal clearance fails. A positive correlation between MAP and Renalase (r = +0.62) suggested a Failed Feedback Loop. ROC analysis identified Serum Renalase as a superior biomarker for distinguishing DKD from T2DM (AUC = 0.92, Sensitivity 85–90%). MAP was highly specific for kidney involvement, with a threshold of 106.40 mmHg yielding 91% specificity for DKD. The DFU group exhibited the highest Renalase levels (39.4 ±5.2 mg/mL), correlating with Wagner Grade severity (r = +0.48). Conclusion: The study confirms that DKD and DFU are manifestations of a singular, systemic pro-inflammatory environment driven by a breakdown in the MAP-Renalase axis. Serum Renalase serves as a robust screening tool for microvascular stress, while MAP serves as a critical confirmatory marker for glomerular damage. Integrating these biochemical and hemodynamic markers provides a superior diagnostic framework for identifying patients at high risk for end-stage renal disease and limb amputation.
- 19 May 2026
- Published by Springer Nature in Research Square
Open AccessThe Hemodynamic-Enzymatic Axis: The Interplay of Mean Arterial Pressure and Renalase in Diabetic Kidney Disease and Diabetic Foot Ulcers
Background & Objective: The global burden of Diabetes Mellitus (DM) has transitioned into a systemic crisis characterized by Diabetic Kidney Disease (DKD) and Diabetic Foot Ulcers (DFU). This study investigates the heart-kidney-limb axis, specifically examining the role of Mean Arterial Pressure (MAP) and Serum Renalase as biomarkers for the transition from metabolic dysfunction to irreversible microvascular damage and mechanical barotrauma. Methods: A cross-sectional study was conducted at a tertiary care hospital in South India from January to July 2025. 120 participants were divided into four groups (n=30 each): Control, Type 2 Diabetes (T2DM), DKD, and DFU. Clinical assessments included blood pressure (to calculate MAP), eGFR, HbA1c, HOMA-IR, and Serum Renalase. Statistical analysis utilized Pearson’s correlation and Receiver Operating Characteristic (ROC) curves to determine diagnostic accuracy. Results: A progressive increase in MAP, Serum Renalase, and HOMA-IR was observed across groups (p < 0.01). Serum Renalase showed a strong negative correlation with eGFR (r = -0.76, p < 0.001), supporting an Accumulation Paradox where levels rise as renal clearance fails. A positive correlation between MAP and Renalase (r = +0.62) suggested a Failed Feedback Loop. ROC analysis identified Serum Renalase as a superior biomarker for distinguishing DKD from T2DM (AUC = 0.92, Sensitivity 85–90%). MAP was highly specific for kidney involvement, with a threshold of 106.40 mmHg yielding 91% specificity for DKD. The DFU group exhibited the highest Renalase levels (39.4 ±5.2 mg/mL), correlating with Wagner Grade severity (r = +0.48). Conclusion: The study confirms that DKD and DFU are manifestations of a singular, systemic pro-inflammatory environment driven by a breakdown in the MAP-Renalase axis. Serum Renalase serves as a robust screening tool for microvascular stress, while MAP serves as a critical confirmatory marker for glomerular damage. Integrating these biochemical and hemodynamic markers provides a superior diagnostic framework for identifying patients at high risk for end-stage renal disease and limb amputation.